Literature DB >> 10223952

Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

D N Fish1, E Abraham.   

Abstract

The pharmacokinetics of clarithromycin and its 14-(R)-hydroxylated metabolite were studied on two separate occasions after nasogastric administration of 500 mg of a clarithromycin suspension to 16 seriously ill adults in an intensive care unit. The clarithromycin suspension appeared to be adequately absorbed, and the pharmacokinetics of neither clarithromycin nor 14-(R)-hydroxyclarithromycin differed significantly between the two dosing periods. No substantial differences in pharmacokinetics were observed compared to previously published studies of other adult populations. Minimal intrapatient variability of pharmacokinetic parameters was observed in these seriously ill patients.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10223952      PMCID： PMC89259     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

Authors:  S Y Chu; L T Sennello; R C Sonders
Journal:  J Chromatogr       Date:  1991-11-15

2.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.

Authors:  J A Paladino; H E Sperry; J M Backes; J A Gelber; D J Serrianne; T J Cumbo; J J Schentag
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

4.  Clarithromycin pharmacokinetics in healthy young and elderly volunteers.

Authors:  S Y Chu; D S Wilson; D R Guay; C Craft
Journal:  J Clin Pharmacol       Date:  1992-11       Impact factor: 3.126

5.  In vitro activity of clarithromycin, cefprozil, and other common oral antimicrobial agents against gram-positive and gram-negative pathogens.

Authors:  D J Ritchie; A W Hopefl; T W Milligan; J E Byrne; M S Maddux
Journal:  Clin Ther       Date:  1993 Jan-Feb       Impact factor: 3.393

6.  Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS.

Authors:  E Vance; M Watson-Bitar; L Gustavson; P Kazanjian
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 7.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

8.  In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents.

Authors:  S Floyd-Reising; J A Hindler; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 9.  Clarithromycin and azithromycin: new macrolide antibiotics.

Authors:  S C Piscitelli; L H Danziger; K A Rodvold
Journal:  Clin Pharm       Date:  1992-02

10.  Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia.

Authors:  J A Ramirez; L Srinath; S Ahkee; A Huang; M J Raff
Journal:  Arch Intern Med       Date:  1995-06-26
View more
  1 in total

Review 1.  Clinical pharmacokinetics of clarithromycin.

Authors:  K A Rodvold
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.